Leukemia Patents (Class 514/19.6)
-
Publication number: 20120028905Abstract: Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.Type: ApplicationFiled: October 11, 2011Publication date: February 2, 2012Applicants: Smithsonian Tropical Research Institute, University of California, San Diego, Oregon StateInventors: Kerry Leigh McPhail, Rebecca Ann Medina, William Henry Gerwick, Douglas Eugene Goeger, Todd Leo Capson
-
Publication number: 20120028903Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.Type: ApplicationFiled: October 6, 2009Publication date: February 2, 2012Applicant: Cambridge Enterprise LimitedInventors: John Trowsdale, Alexander Barrow, Richard Farndale
-
Patent number: 8105603Abstract: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling.Type: GrantFiled: March 16, 2009Date of Patent: January 31, 2012Assignee: Genentech, Inc.Inventors: Robert F. Kelley, Darshana Ramesh Patel
-
Publication number: 20120021999Abstract: The invention relates to chimeric peptides useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors.Type: ApplicationFiled: March 29, 2010Publication date: January 26, 2012Inventors: Angelita Rebollo Garcia, Alphonse Garcia, Xavier Cayla, Issam Arrouss, Katy Billot, Angelique Godet
-
Publication number: 20120014869Abstract: Provided are MUC 18 targeting peptides which may be used, e.g., to therapeutically target B-I lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC 18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer.Type: ApplicationFiled: October 15, 2009Publication date: January 19, 2012Applicant: The Board of Regents of the Univesity of Texas SystemInventors: Fernanda Staquicini, Renata Pasqualini, Wadih Arap
-
Publication number: 20120003181Abstract: The present invention describes a novel retinoid-responsive nucleic acid, and a novel protein. Further, the invention describes the use of such a nucleic acid or protein in various diseases, and for the treatment, the diagnosis and prognosis of various diseases, and also for a method for the prognosis of responsiveness to retinoids.Type: ApplicationFiled: June 9, 2009Publication date: January 5, 2012Inventors: Johan R. Lillehaug, Pendino Frederic
-
Publication number: 20110319317Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.Type: ApplicationFiled: March 3, 2010Publication date: December 29, 2011Applicant: OPKO CuRNA, LLCInventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
-
Publication number: 20110311555Abstract: Methods and compositions for the diagnosis, prognosis and/or treatment of B cell chronic lymphocytic leukemia associated diseases are disclosed.Type: ApplicationFiled: November 19, 2009Publication date: December 22, 2011Applicant: THE OHIO STATE UNIVERSITYInventors: Carlo M. Croce, Yuri Pekarsky
-
Publication number: 20110311445Abstract: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.Type: ApplicationFiled: May 9, 2011Publication date: December 22, 2011Applicant: MORPHOTEK, INC.Inventors: Vernon L. Alvarez, Matthew A. Gonda
-
Publication number: 20110305750Abstract: Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the cytoplasmic domain is capable of inhibiting in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease.Type: ApplicationFiled: December 17, 2009Publication date: December 15, 2011Applicant: Angiochem Inc.Inventors: Richard Beliveau, Denis Gingras, Carine Nyalendo
-
Publication number: 20110301088Abstract: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.Type: ApplicationFiled: March 4, 2011Publication date: December 8, 2011Inventors: Stephan D. Parent, Steven R. Schow
-
Publication number: 20110300167Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor CXCR5. The CXCR5 receptor compounds are derived from the intracellular loops and domains of the CXCR5 receptor. The invention also relates to the use of these CXCR5 receptor compounds and pharmaceutical compositions comprising the CXCR5 receptor compounds in the treatment of diseases and conditions associated with CXCR5 receptor modulation such as autoimmune diseases including lupus, HIV and rheumatoid arthritis, Primary Sjogren's Syndrome, chronic lymphocytic leukemia, Burkitt Lymphoma, colon and breast cancer tumor metastasis, Multiple Sclerosis and compromised immune function.Type: ApplicationFiled: November 4, 2009Publication date: December 8, 2011Inventors: Thomas J. McMurry, Athan Kuliopulos, Lidija Covic
-
Publication number: 20110293726Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosed chimeric therapeutics.Type: ApplicationFiled: April 8, 2011Publication date: December 1, 2011Inventors: Miguel de los Rios, John Mendlein, Timothy L. Bullock, Kenneth J. Oh, Patrick T. Johnson, Jacek Ostrowski, Stephanie de los Rios
-
Publication number: 20110288021Abstract: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.Type: ApplicationFiled: November 20, 2009Publication date: November 24, 2011Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: George P. Tuszynski, John F. Wong, Taffy Williams
-
Publication number: 20110288004Abstract: The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.Type: ApplicationFiled: June 21, 2007Publication date: November 24, 2011Inventors: D. Grant McFadden, Alexandra R. Lucas, John W. Barrett
-
Publication number: 20110280876Abstract: A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies.Type: ApplicationFiled: June 29, 2011Publication date: November 17, 2011Applicants: IVS INSTITUT DES VAISSEAUX ET DU SANG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: JEAN PLOUET, Monica Alemany
-
Publication number: 20110269686Abstract: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: ApplicationFiled: July 8, 2011Publication date: November 3, 2011Applicant: BIOKINE THERAPEUTICS LTD.Inventors: Nobutaka FUJII, Hirokazu TAMAMURA, Akira HORI
-
Publication number: 20110262455Abstract: A method of treating a proliferative disorder, and a pharmaceutical composition for use in such a method, comprises administering to the patient a combination of an agonist of a death receptor and an antagonist of Egr-1.Type: ApplicationFiled: October 9, 2009Publication date: October 27, 2011Applicant: National University of IrelandInventors: Afshin Samali, Eva Szegezdi, Devalingam Mahalingam, Alessandro Natoni
-
Publication number: 20110263486Abstract: The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y is —NRaRb, —NRc?ONRaRb, —NRcC?SNRaRb, —NRcC?NRdNaRb, heterocycle, —C?ONRaRb, heterocycle, or aryl; n is 0 to 8; m is 0, or 1; r is 0 to 3; t is 0 to 3; X is O or N; Z is CH2, C?O, C?S or a single bond; Z1 is CO—R2, CS—R2, (CH2)t—R2 or the side-chain of a naturally occurring amino acid; Z2 is CO—R2, CS—R2 or (CH2)t—R3 or the side-chain of a naturally occurring amino acid; Z3 is CO—R2, CS—R2 or (CH2)t—R4 or the side-chain of a naturally occurring amino acid; Z4 is H, alkyl, alkoxy, or cycloalkyl; R1, R2, R3, and R4 are independently from each other H, OH, SH, NH2, CN, NO2, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkylthio, haloalkyloxy, hydroxyalkyl, hydroxyalkylamino, alkylamino, alkylaryl, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxyalkyl, alkoxy, aryloxy, heteroaryl, aryl, or halogen.Type: ApplicationFiled: March 11, 2011Publication date: October 27, 2011Applicant: 4SC AGInventors: Johann LEBAN, Martin KRALIK
-
Publication number: 20110262432Abstract: A mutated protein includes the sequence of wild type netrin 4, represented by SEQ ID NO: 2, wherein at least one amino acid of the amino acids at position (13, 68, 183, 205, 234, 331, 332, 353, 472, 515, 589, 625, 626, 627) and (628) is mutated enabling thus to confer 1 to 15 mutations to the wild type protein, or, truncated protein derived from the mutated protein, wherein the 19 first contiguous, or the 31 first contiguous amino acids at the N-terminus part of the mutated protein are deleted; and/or the mutated protein being deleted of all amino acids located after the amino acid in position (477) or of all amino acids located after the amino acid in position (515).Type: ApplicationFiled: July 16, 2009Publication date: October 27, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean Plouet, Isabelle Clarisse Solange Plouet, Claire Charlotte Plouet, Anne Florence Plouet, Laurence Leconte, Esma Lejmi
-
Patent number: 8034781Abstract: The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.Type: GrantFiled: June 27, 2007Date of Patent: October 11, 2011Assignee: Wake Forest University Health SciencesInventors: E. Ann Tallant, Patricia E. Gallagher, Carlos M. Ferrario
-
Publication number: 20110237498Abstract: The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament, comprising an extracellular domain of SIRP? (CD172a) or functional derivatives which bind to human CD47.Type: ApplicationFiled: December 17, 2009Publication date: September 29, 2011Applicant: NOVARTIS AGInventors: Marianne Raymond, Marie Sarfati, Karl Welzenbach, Maximilian Woisetschlaeger
-
Publication number: 20110236428Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.Type: ApplicationFiled: October 21, 2009Publication date: September 29, 2011Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
-
Publication number: 20110237497Abstract: A composition of a glucocorticoid receptor (GR) ligand, or analog thereof, and a V-ATPase inhibitor, or analog thereof. A method for administering such composition to a cell either to increase glucocorticoid transrepression activity or to increase glucocorticoid transactivation activity in the cell. Also, a method for treating a subject having an inflammatory or auto-immune disease by administering such composition.Type: ApplicationFiled: November 18, 2010Publication date: September 29, 2011Inventors: HUAQIANG ERIC XU, Yong Xu, Yuanzheng He
-
Publication number: 20110230422Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used to purge an ex vivo hematopoietic stem cell culture of cancer cells for engraftment in a mammal by administering the composition to the ex vivo hematopoietic stem cell culture in an effective amount.Type: ApplicationFiled: December 23, 2009Publication date: September 22, 2011Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Mary A. Richter, Michael Clark-Lewis, Hassan Salari
-
Publication number: 20110223133Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.Type: ApplicationFiled: April 13, 2011Publication date: September 15, 2011Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Masaaki KOSAKA, Shuji Ozaki, Yuji Wakahara
-
Patent number: 8017585Abstract: Peptides, their amides, esters or salts, which have CXCR4 antagonistic action, have therapeutic effects for cancer and chronic rheumatoid arthritis.Type: GrantFiled: July 11, 2008Date of Patent: September 13, 2011Assignee: Biokine Therapeutics Ltd.Inventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori
-
Publication number: 20110218152Abstract: The present invention is directed to polypeptides (e.g., fragments) derived from P-glycoprotein and caveolin-1 which are capable of inhibiting the interaction between these two proteins. Inhibition of this interaction leads to increase of efflux of compounds that are transported by P-gp. The invention further includes methods of treating patients having diseases that benefit from increased P-gp-mediated efflux. Such diseases include neoplasms such as cancer and neurological diseases such as neurodegenerative diseases.Type: ApplicationFiled: October 19, 2007Publication date: September 8, 2011Inventors: Richard Beliveau, Michel Demeule, Stephane Barakat, Jonathan Michaud-Levesque
-
Patent number: 7994135Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: August 3, 2007Date of Patent: August 9, 2011Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20110190220Abstract: The present invention pertains to the use of defensin ?1 and/or defensin ?4, as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib.Type: ApplicationFiled: July 17, 2009Publication date: August 4, 2011Inventors: Béatrice Turcq, Gabriel Etienne, Maryse Dupouy, François-Xavier Mahon, Bertrand Garbay, Patricia Costaglioli
-
Publication number: 20110190219Abstract: Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described.Type: ApplicationFiled: March 7, 2008Publication date: August 4, 2011Inventor: Svetomir N. Markovic
-
Publication number: 20110189095Abstract: Provided are methods and compositions for selectively targeting CRKL through the use of targeting peptides. Selective targeting of secreted CRKL through the use of a targeting peptide may be used, for example, in the treatment of cancer to deliver a chemotherapeutic compound, fusion protein, or fusion construct to a cancer cell or tissue.Type: ApplicationFiled: June 19, 2009Publication date: August 4, 2011Applicant: The Board of Regents, of the University of Texas SystemInventors: Wadih Arap, Paul J. Miniz, Renata Pasqualini
-
Publication number: 20110189202Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.Type: ApplicationFiled: September 23, 2009Publication date: August 4, 2011Applicant: Yeda Research And Development Co., Ltd.Inventors: Idit Shachar, Inbal Binsky, Mirko Sobotta
-
Publication number: 20110183888Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling, wherein these diseases or disorders are selected from autoimmune disorders, cardiovascular diseases, cancerous diseases, diabetes, including diabetes type 1 or type 2, inflammatory diseases, hair loss, including Alopecia areata, diseases of the lung, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, viral infectious diseases and depressive disorders.Type: ApplicationFiled: June 2, 2009Publication date: July 28, 2011Inventor: Christophe Bonny
-
Publication number: 20110183918Abstract: The present invention relates to a method of treating leukemia using rice prolamin, and a pharmaceutical composition for treating leukemia, comprising an effective amount of rice prolamin together with one or more pharmaceutically acceptable carriers or excipients. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (PBMC) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia U937 cells. The rice prolamin is gluten-free, thus will not trigger gastrointestinal allergic reaction.Type: ApplicationFiled: July 28, 2010Publication date: July 28, 2011Applicant: MACKAY MEMORIAL HOSPITALInventors: Yu-Jen Chen, Hui-Fen Liao, Yu-Yawn Chen
-
Publication number: 20110177088Abstract: The invention relates to methods for treating and diagnosing hematologic malignancies, Chronic lymphocytic leukemia and Small Lymphocytic Lymphoma in particular, using PD-1 ligands (PD-L1, PD-L2 or anti-PD-1 antibodies).Type: ApplicationFiled: August 14, 2008Publication date: July 21, 2011Applicant: UNIVERSITE DE LA MEDITERRANEEInventors: Daniel Olive, Luc Xerri, Alemseged Truhneh
-
Publication number: 20110165160Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: December 10, 2010Publication date: July 7, 2011Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20110166079Abstract: Methods of treating chronic lympocytic leukemia, chronic myelogenous leukemia, and breast cancer in a subject by administering an ApoE peptide are disclosed.Type: ApplicationFiled: July 1, 2009Publication date: July 7, 2011Applicant: COGNOSCI, INC.Inventors: Michael P. Vitek, Dale J. Christensen
-
Publication number: 20110160130Abstract: Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a combination of a non-peptide TPO receptor agonist or a peptide TPO mimetic and a cell cycle signalling inhibitor compound to such mammal.Type: ApplicationFiled: August 2, 2010Publication date: June 30, 2011Inventor: Connie ERICKSON-MILLER
-
Patent number: 7964566Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: August 3, 2007Date of Patent: June 21, 2011Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Patent number: 7964567Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: August 3, 2007Date of Patent: June 21, 2011Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20110144033Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: ApplicationFiled: February 3, 2011Publication date: June 16, 2011Applicant: CEPHALON, INC.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Publication number: 20110129461Abstract: The presently disclosed subject matter generally relates to methods and compositions for modulating MAT II activity. More particularly, the presently disclosed subject matter relates to methods and compositions for inhibiting the expression of MAT II ? subunit in a subject via RNAi by administering siRNA or shRNA molecules directed to MAT II ? subunit. In some embodiments, the methods and compositions of the presently disclosed subject matter generally relates to the treatment of cancer. More particularly, the methods and compositions of the presently disclosed subject matter relates to the inhibition of MAT II ? subunit for the treatment of leukemia.Type: ApplicationFiled: April 7, 2009Publication date: June 2, 2011Applicant: UNIVERSITY OF CINCINNATIInventors: Malak Kotb, Arthur M. Geller
-
Publication number: 20110124572Abstract: The present invention provides a method for modulating the activity of Rac1, comprising modifying the phosphorylation state of Ser179 in syndecan-4 through influencing the interaction between syndecan-4 and the guanin nucleotide exchange factor of Rac1 (RacGEF) named Tiam1 in a GTP-dependent manner. In particular, methods are provided for enhancing the epithelial phenotype of a cell and for initiating the polarization of a cell by increasing the de-phosphorylation of said Ser179 of syndecan-4, and for enhancing the migratory phenotype of a cell and for initiating the neuronal differentiation of a cell by increasing the phosphorylation of said Ser179 of syndecan-4. Polypeptides for use in modulating the activity of the small GTPase Rac are also provided, as well as a method for identifying an agent capable of indirectly modulating the activity of the small GTPase Rac 1.Type: ApplicationFiled: July 24, 2009Publication date: May 26, 2011Inventors: László Szilák, Anikó Keller-Pintér, Tamás Letoha, József Tímár
-
Publication number: 20110123524Abstract: The present invention relates to methods for treating neoplasias in a mammalian subject. In particular, the invention provides methods for treating lymphomas, including forms of non- Hodgkin lymphoma. In one embodiment, these methods involve reducing tumor necrosis factor signaling.Type: ApplicationFiled: January 22, 2009Publication date: May 26, 2011Inventors: Michael David, Irene Munk Pedersen
-
Publication number: 20110118193Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount.Type: ApplicationFiled: December 23, 2009Publication date: May 19, 2011Inventors: Christopher R. Tudan, Ahmed Merzouk, Lakhdar Arab, Geeta Saxena, Connie J. Eaves, Joanne Cashman, Ian Clark-Lewis, Mary A. Richter, Michael Clark-Lewis, Hassan Salari
-
Publication number: 20110118192Abstract: The present invention relates to compositions and methods that may be used to diagnose and treat cancer, particularly T-cell leukemia. According to one preferred embodiment of the present invention, methods are provided for determining whether reducing or blocking NOTCH-1 activation will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient, including T-cell leukemia, myeloleukemia, neuroblastoma, breast cancer, and ovarian cancer. The methods generally include determining if the patient harbors one or more mutations in a PTEN coding region. In particular, the methods may be used to determine whether reducing or blocking NOTCH-1 activation, with one or more ?-secretase inhibitors, will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient.Type: ApplicationFiled: February 1, 2008Publication date: May 19, 2011Applicant: TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Adolfo A. Ferrando, Teresa Palomero, Maria Luisa Sulis
-
Publication number: 20110092428Abstract: A method of detecting abnormal hematopoiesis in a subject based on abnormal expression of ZFP36L2, a method of controlling hematopoiesis in a subject altering the level or activity of ZFP36L2 protein in the subject, a method of screening for compounds that modulate hematopoiesis based on changes to ZFP36L2 expression, and compounds identified thereby.Type: ApplicationFiled: July 1, 2008Publication date: April 21, 2011Applicant: The United States of America,as represented by the Secretary ,Department of Healthyand Human ServiceInventors: Deborah J. Stumpo, Perry J. Blackshear
-
Publication number: 20110077190Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).Type: ApplicationFiled: May 21, 2009Publication date: March 31, 2011Inventors: Jan-Eric Ahlfors, Khalid Mekouar
-
Publication number: 20110076295Abstract: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.Type: ApplicationFiled: December 9, 2010Publication date: March 31, 2011Inventors: Atul Varadhachary, Rick Barsky, Federica Pericle, Karel Petrak, Yenyun Wang